INTERPHEX 2025: Evolution of Flow Sensor Technologies in Manufacturing
Sitting down with the PharmTech Group at INTERPHEX 2025, Michael Franco, global sales director at PSG Biotech, discussed the recent advancements in pharmaceutical flow sensor technology.
Editor's note: this interview was originally published on PharmTech.com.
Michael Franco, global sales director at PSG Biotech, sat down with the PharmTech Group at INTERPHEX 2025 and discussed how recent advancements in pharmaceutical flow sensor technology primarily focus on improving measurement accuracy as drug production becomes more expensive and precise. He points out a key development, which is the enhancement of Coriolis single-use flow meters. These meters now feature a higher turndown ratio. This enhancement allows a single sensor to accurately measure both high and low flow rates. With this innovation, inventory needs can be reduced, and sensor usability across various process conditions is extended, which improves sustainability.
“When we talk about high turndown ratio, it's very good for the industry, because with one sensor, you can measure more than just low flows or high flows. So, in terms of sustainability, there's less need for inventory, and the sensor can be used for longer, because it can be operated in different process conditions. [In] terms of the future, we're adding more digital communication platforms so customers can communicate to the sensors in different ways, making sure that the sensors talk to pumps, and to get a really good performance between the two. [Those] are the things that probably are going to be asked more and more from customers,” Franco says.
Looking forward, this integration of digital communication platforms to enhance sensor interoperability is expected to enable better coordination with pumps and optimize system performance. These advancements are increasingly demanded by customers for improved bioprocessing applications, including tangential flow filtration (TFF) and chromatography skids. The ongoing adoption of these technologies as observed at INTERPHEX, notes Franco, highlights their growing importance in pharmaceutical manufacturing.
INTERPHEX 2025 occurred in New York City on April 1–3.
Click above to view the full interview.
Click here for more conference coverage.
About the speaker
Michael Franco is global sales director at PSG Biotech.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
